Demonstrates ongoing commitment to innovation in ophthalmics for Shire P-321 is a Phase 2 investigational topical treatment for dry eye disease Lexington, Massachusetts, and Durham, North Carolina, US – May 1, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) and Parion Sciences, Inc. today announced they have entered into an agreement granting Shire exclusive worldwide … Continue reading Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
↧